Efficacy of High-dose Liraglutide 3.0 mg in Patients with Poor Response to Bariatric Surgery: Real-world Experience and Updated Meta-analysis.
Federica VinciguerraCarla Di StefanoRoberto BarattaAlfredo PulvirentiGiuseppe MastrandreaLuigi PiazzaFabio GuccioneGiuseppe NavarraLucia FrittittaPublished in: Obesity surgery (2024)
Liraglutide 3 mg emerges as a viable option for significant weight loss in patients experiencing IWL or WR after BS. Its inclusion in a multimodal, sequential obesity treatment approach proves promising.
Keyphrases
- weight loss
- bariatric surgery
- high dose
- systematic review
- end stage renal disease
- roux en y gastric bypass
- newly diagnosed
- chronic kidney disease
- obese patients
- gastric bypass
- type diabetes
- prognostic factors
- insulin resistance
- low dose
- weight gain
- body mass index
- patient reported outcomes
- physical activity
- combination therapy
- glycemic control